$1 Trial Offer - Realtime Screener -- Try out our Realtime Product, GetStockIdeas. The advanced screener tool is a momentum trader's dream!

Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Loading IDRA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.39%79.771.3%$810.55m
BIIBBiogen Inc.
0.43%308.171.2%$594.94m
AMGNAmgen Inc.
1.02%171.971.1%$507.80m
CELGCelgene Corporation
0.82%108.790.8%$480.49m
MDVNMedivation, Inc.
0.14%80.351.5%$457.05m
REGNRegeneron Pharmaceuticals, Inc.
0.68%402.973.4%$311.23m
ILMNIllumina, Inc.
1.61%172.214.2%$212.71m
ALXNAlexion Pharmaceuticals, Inc.
0.36%129.632.7%$186.81m
BMRNBioMarin Pharmaceutical Inc.
1.32%96.224.2%$183.84m
VRTXVertex Pharmaceuticals Incorporated
0.74%97.092.2%$112.19m
INCYIncyte Corporation
1.17%81.042.5%$106.31m
IONSIonis Pharmaceuticals, Inc.
1.75%30.9011.4%$96.76m
AAgilent Technologies, Inc.
0.13%47.320.9%$93.68m
TSROTESARO, Inc.
1.44%86.4616.2%$88.66m
EXASExact Sciences Corporation
0.74%19.1922.9%$86.20m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera's immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.